Parkinson’s Disease

As a chronic neurodegenerative disease affecting the CNS, Parkinson’s Disease present progressive symptoms such as slow movements, tremor, muscle stiffness and cognitive impairment. 

Parkinson’s Disease is a synucleopathic disease. It is a consequence of the loss of dopaminergic neurons associated with the anatomopathological landmark, the presence of Lewy Bodies, that are intracellular aggregation of proteins. Among these proteins can be found the Synuclein, the Ubiquitin and many others. Besides the loss of dopaminergic neurons in Parkinson’s Disease, there is the loss of a number of brain areas.

Parkinson’s Disease Assays and models

in vitro models

in vivo models

  • Key-Obs, our preferred partner expert in behavioural models of neurological disorders, offers behavioural tests to assess compound efficacy on pharmacological PD models (6-OHDA)

Are you currently working on compounds targeting Parkinson’s Disease?

Please contact us for any additional information and we will gladly come back to you. We can also set up a dedicated meeting between you and our experts to discuss our CRO services and your research needs.

Jean-Charles BIZOT, PhD
CEO & Behavioral Pharmacologist
GM & Behavioral Pharmacologist
Bruno Buisson, PhD
Co-Founder, President & CSO
Bob Petroski, PhD
CSO in vitro cell
Jeffrey Hubbard, PhD
CSO in vitro slice